Ractigen Therapeutics, a Shanghai-based biotechnology company, raised over $31M in funding. This round was led by Guozhong Capital and included various other investors. The funds will be used to advance clinical trials for their saRNA assets. The company has three differentiated assets in clinical-stage development.
Company Information
Company
Ractigen Therapeutics
Location
Nantong, Jiangsu, China
About
Ractigen Therapeutics was founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang. Ractigen is a late-stage preclinical pharmaceutical company devoted to creating groundbreaking therapies based on the RNAa platform. RNAa utilizes short duplex RNAs, known as small activating RNAs (saRNA), to specifically up-regulate targeted endogenous genes for boosting therapeutic protein production. Supporting its core platform, Ractigen Therapeutics has created the SCAD delivery system allowing enhanced biodistribution throughout extrahepatic tissue and built a rich pipeline of first-in-class candidate medicines for patients with unmet genetic disorders.
Ractigen Therapeuticswww.ractigen.com
SOURCE Ractigen Therapeutics
Related People
Suggested for you
2 contacts
Verified contactsLong-Cheng, Co-founder, President & CEO hidden
Predictive Intelligence
Strategic
ML-powered predictions for Ractigen Therapeutics's next move
NantongHealth CareScience And Engineering